Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zimmer boosts biologics with ETEX buy

This article was originally published in Clinica

Executive Summary

Orthopedic firm Zimmer has bolstered its biologics portfolio by acquiring ETEX Holdings for an undisclosed fee. The Cambridge, Massachusetts firm has several bone void filler products including the injectable Beta-bsm, Gamma-bsm putty, CarriGen and EquivaBone. Zimmer’s existing biologics offering includes Gel-One, an injectable hyaluronate gel approved for the treatment of osteoarthritis of the knee; Chondrofix, an osteochondral allograft for osteochondral lesions in the ankle; and the Denovo NT juvenile cartilage implant for the repair of articular cartilage damage. “ETEX's innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease," stated Joseph Cucolo, president of Zimmer Americas. The purchase is Zimmer’s second this year: in April, it splashed out $13.35bn on Biomet, propelling it to the number-two position in the overall orthopedic market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel